Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

  title={Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160},
  author={Phillip W Berman and Timothy J. Gregory and Lavon Riddle and Gerald Nakamura and Mark A. Champe and James P. Porter and F Wurm and Robert D. Hershberg and Elaine K Cobb and Jorg W. Eichberg},
THE development of a vaccine to provide protective immunity to human immunodeficiency virus type 1 (HIV-1), the virus causing AIDS, would be the most practical method to control its spread. Subunit vaccines consisting of virus envelope glycoproteins, produced by recombinant DNA technology, are effective in preventing viral infections1. We have now used this approach in the development of a candidate AIDS vaccine. Chimpanzees were immunized with recombinant forms of the HIV-1 glycoproteins gp120… 

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

The results of this study indicate that vaccine-mediated protection against intravenous infection with heterologous HIV-1 strains of the same subtype is possible with some immunogens.

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

It is demonstrated that immunization with recombinant gp120 derived from a T cell-adapted isolate prevented infection by a heterologous primary isolate of HIV-1, and in vitro virus neutralization assays utilizing primary isolates cultured in PBMC may be imperfect indicators of protection in vivo.

Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.

To evaluate the potential protective efficacy of a live recombinant human immunodeficiency virus type 1 (HIV-1) canarypox vaccine candidate, two chimpanzees were immunized five times with ALVAC-HIV-1

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

Results indicate that immunization with viral envelope antigens alone is sufficient to elicit protective immunity against a primate immunodeficiency virus.

Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine

It is demonstrated that a multiantigen subunit protein vaccine was able to prevent the development of disease induced in rhesus monkeys by a partially heterologous AIDS virus.

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

The protective efficacy of anti-V3 domain antibody in vivo is demonstrated and it is proposed that this antibody is potentially useful as both a pre- and post-exposure prophylactic agent.

Human studies in the development of human immunodeficiency virus vaccines.

  • R. Dolin
  • Biology, Medicine
    The Journal of infectious diseases
  • 1995
Serum from vaccinees can neutralize laboratory-adapted HIV-1 strains in vitro but not primary isolates; the significance of this observation is unknown.

Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys

INFECTION of macaques with simian immunodeficiency virus (SIV)1,2 and human immunodeficiency virus type 2 (HIV-2) 3,4 are useful models for studies of immunotherapy and vaccination against HIV as



Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

  • P. BermanJ. Groopman L. Lasky
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1988
The immune response elicited against the rgp120 was not effective in preventing viral infection after intravenous challenge with HIV-1 and the implications of these results on HIV- 1 vaccine development are discussed.

Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120

Chimpanzees immunized with gp120 purified from human T-cell lymphotrophic virus type IIIB-infected cell membranes and challenged with the homologous virus, HTLV-IIIB became infected with HIV, indicating that the immune response elicited by immunization with gp 120 formulated in alum was not effective in preventing infection with HIV-1.

Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.

  • A. PrinceB. Horowitz F. Rey
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 1988
HIVIG recipients did not differ significantly from the incubation period seen in a control animal that received a normal anti-HIV-free immunoglobulin, and these findings may have implications for understanding the failure of experimental vaccines to protect against HIV challenge in chimpanzee experiments.

Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.

It is demonstrated that immunization with a purified viral protein can provide significant protection against primary genital infection by HSV-2 in guinea pigs.

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Three of 16 human monoclonal antibodies enhanced human immunodeficiency virus type 1 (HIV-1) infection of MT-2 target cells by means of a mechanism that is dependent on complement by demonstrating that hu-mAbs directed against the HIV-1 transmembrane glycoprotein gp41 can enhance HIV- 1 infection in vitro.

Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1.

The significance of the RIP assay for evaluating immune responses was confirmed by analysis showing that the percentage of immunized baboons that developed in vitro HIV-1 serum neutralizing responses was greatest in groups that also exhibited high anti-rgp120 RIP titers.

Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

The principal epitope that elicits fusion-inhibiting antibodies is located in the central portion of gp120, and a 24-amino acid peptide (RP135, amino acids 307-330) completely blocks fusion inhibition activity of both antisera and the activity of serum from a chimpanzee infected with HTLV-IIIB.

Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA.

A vaccine formulated from hepatitis B surface antigen (HBsAg) produced by a recombinant strain of the yeast Saccharomyces cerevisiae was administered to two groups of human volunteers composed of 37 healthy, low-risk adults, the first reported use in man of a vaccine prepared by recombinant DNA technology.

Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

Antibodies directed against the recombinant molecule were found to react with the envelope glycoprotein produced in virus-infected cells, which should provide sufficient quantities of the AIDS retrovirus envelope protein for biological and vaccination studies.